Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life‐changing medicines, strengthen how health is understood and managed, and support the communities we serve. This is hard, urgent, self‐less work—but it's work worth doing. We are a global healthcare leader headquartered in Indianapolis, and in Mexico we have been making medicines since 1908. Driven by our enduring values of Integrity, Excellence, and Respect for People, we put people first — in our labs, in our communities, and in our workplaces.
The Opportunity Neuroscience
Neuroscience is one of Lilly's most enduring scientific commitments, and Alzheimer's disease is among the fastest-moving fields in medicine — moving from symptomatic management toward biologically confirmed diagnosis, earlier detection, and intervention in the early symptomatic stages of disease. As a Medical Science Liaison (MSL), you will be a credible, field-based scientific partner: translating complex evidence into clinical practice, building trust‐based relationships with healthcare experts, and generating the insights that shape Lilly's medical strategy in México — in a therapeutic area where the diagnostic pathway itself must be strengthened alongside the science.
Maintain expert command of the evidence across Alzheimer's disease and the wider neurodegeneration landscape — amyloid and tau biology, fluid and imaging biomarkers, cognitive and functional endpoints, and Lilly's current and pipeline neuroscience assets, engaging on investigational assets only in a reactive, compliant manner. Translate clinical trial data, real‐world evidence, HEOR outputs, and updates to diagnostic criteria and clinical guidance (NIA‐AA, IWG, AAN, Alzheimer's Association appropriate‐use recommendations,



Academia Mexicana de Neurología) into clear, balanced, guideline‐aligned scientific narratives. Discuss safety and monitoring considerations for this class of therapies — including imaging surveillance requirements and patient risk‐stratification — with the balance and rigor the topic demands. Map, prioritize, and build trust‐based partnerships with scientific and clinical experts across neurology, cognitive and behavioral neurology, geriatrics, psychiatry, neuroradiology and nuclear medicine, neuropsychology, internal medicine, and primary care — recognizing that Alzheimer's care depends on a diagnostic and treatment chain rather than on a single prescriber. Engage the wider care team whose readiness determines whether evidence reaches patients — neuropsychology, imaging and infusion services, nursing, laboratory, and hospital administration colleagues. Characterize the local diagnostic pathway end to end — cognitive screening, specialist referral, biomarker confirmation, imaging access and reporting capacity, and treatment‐monitoring infrastructure — and identify where it breaks down. Support scientific education that strengthens diagnostic confidence and appropriate patient identification, including disease staging, differential diagnosis, and interpretation of biomarker results. Map centers of excellence and emerging referral networks,



recognizing that Alzheimer's diagnostic and treatment capability in México is concentrated in a limited number of institutions with markedly different levels of readiness. Support investigator‐initiated trials, real‐world evidence projects, registries, and publication activities in partnership with the broader Medical Affairs team.
Partner with Access, HEOR, Regulatory, Commercial, Marketing, and Compliance colleagues so Medical Affairs contributes as a strategic, evidence‐based voice across the full product lifecycle — pre‐launch, launch, and post‐launch. Uphold Lilly's zero‐tolerance ethics culture and ensure every activity meets Lilly integral standards.
either path works) Advanced degree in health sciences (MD, PharmD, PhD, or MSc) with at least 2 years of clinical, research, industry, or Medical Affairs experience — training or practice in neurology, geriatrics, psychiatry, or neuroscience is a strong advantage, OR Bachelor's degree in life sciences with 5+ years of relevant clinical, research, or pharmaceutical industry experience in a therapeutic area related to neuroscience or neurodegenerative disease.
Fluent English and Spanish, able to present complex scientific data and manage rigorous Q&A; in both languages.
Digital fluency — comfort operating within CRM ecosystems (Veeva CRM), literature databases (PubMed, Embase, Cochrane, UpToDate, ClinicalKey), virtual‐engagement platforms (MS Teams), and insight/analytics dashboards; Mobility — willing and able to travel approximately 50–60% nationally, including overnight, complemented by a parallel omnichannel engagement model for virtual interactions.
Working knowledge of Alzheimer's diagnostic and outcome tools — cognitive and functional instruments (MMSE, MoCA, CDR‐SB, ADAS‐Cog, ADCS‐ADL), CSF

📌 Medical Science Liaison — Neuroscience (Ciudad de México)
🏢 412 Eli Lilly y Compañía de México S.A de
📍 Ciudad de México